Trial · NCT07896681
Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
NCT07896681, Phase 2, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study. Trials, record NCT07896681. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896681
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study
- NCT number
- NCT07896681
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 46 participants, estimated
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Toripalimab, Cetuximab, Irinotecan
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | From baseline until disease progression or initiation of new anticancer therapy, assessed up to approximately 24 months. | The percentage of participants who achieve a complete response (CR) or partial response (PR), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
| Secondary | Duration of Response (DoR) | From the first documented CR or PR until disease progression or death, assessed up to approximately 24 months. | Duration of response is defined as the time from the first documented complete response (CR) or partial response (PR) to the first documented disease progression or death from any cause, whichever occurs first, among participants achieving CR or PR, according to RECIST version 1.1. |
| Secondary | Disease Control Rate (DCR) | From baseline until disease progression or initiation of new anticancer therapy, assessed up to approximately 24 months. | The percentage of participants who achieve a complete response (CR), partial response (PR), or stable disease (SD), as assessed by investigators according to RECIST version 1.1. |
| Secondary | Progression-Free Survival (PFS) | From the first dose of study treatment until disease progression or death, assessed up to approximately 24 months. | Progression-free survival is defined as the time from the first dose of study treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From the first dose of study treatment until death from any cause, assessed up to approximately 24 months. | Overall survival is defined as the time from the first dose of study treatment to death from any cause. |
| Secondary | Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From the first dose of study treatment through 90 days after the last dose. | The number and percentage of participants experiencing adverse events (AEs) or serious adverse events (SAEs) will be assessed. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Safety assessments will include laboratory tests, vital signs, electrocardiograms, and physical examinations. |
| Other | Change From Baseline in Plasma Circulating Tumor DNA Variant Allele Frequency (VAF) at Week 8 | Baseline and Week 8 after the first dose of study treatment. | Plasma circulating tumor DNA (ctDNA) will be assessed using targeted next-generation sequencing (NGS) at baseline and Week 8. The maximum variant allele frequency (VAF) among predefined tumor-associated somatic variants will be recorded for each participant at each time point. VAF will be expressed as a percentage. The change from baseline will be calculated as the Week 8 VAF minus the baseline VAF and reported in percentage points. Negative values indicate a reduction in ctDNA VAF. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896681
GET https://conductscience.org/api/trials/v1/NCT07896681/registered